MHRA regulatory strategy and international cooperation

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has expanded its focus on international cooperation and future technological integration.

In September 2026, the MHRA strengthened its regulatory partnership with Malaysia. Following meetings in Kuala Lumpur between MHRA Chief Executive Lawrence Tallon and Malaysia’s Minister of Health, YB Datuk Seri Dr Dzulkefly Ahmad, both parties committed to deepening collaboration regarding medicines, medical devices, and clinical trials. The initiative aims to accelerate innovation and create efficient approval pathways through knowledge-sharing and the exchange of regulatory best practices.

By October 2026, the MHRA unveiled its 2030 strategy, which prioritizes patient safety, precision medicine, and the regulation of artificial intelligence (AI). The agency plans to launch an MHRA Centre for AI and Digital Health and intends to establish a benefit and risk framework for AI-driven medical products by 2027. This strategic shift occurs as AI accelerates drug discovery timelines, though industry experts note that human clinical trials remain the primary determinant for regulatory approval.